(NASDAQ:MREO) is up 10% on news of positive phase 2 data.

May 9, 2022

Statistically significant inhibition of blood neutrophil elastase activity of up to 90% in patients in both high and low dose alvelestat groups throughout the 12-week dosing period

Statistically significant reductions in the biomarkers Aα-val360 and desmosine at the high dose demonstrating clear impact of alvelestat on the pathogenic pathway of AATD-lung disease

No safety signals were associated with alvelestat

Conference Call Today at 10:30 a.m. ET

https://www.globenewswire.com/news-release/2022/05/09/2438434/0/en/Mereo-BioPharma-announces-Positive-Top-Line-Efficacy-and-Safety-Data-from-ASTRAEUS-Phase-2-Trial-of-Alvelestat-in-Alpha-1-Antitrypsin-Deficiency-associated-Emphysema.html

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.